Across its top 20 institutional holders, BMRN's holder base skews toward low-concentration, low-turnover investors on average (avg. concentration score 5/100, avg. turnover score 29/100).

Quarterly Activity

Recent Activity

+$5.4B

Total Buy Value

$5.7B

Total Sell Value

New buy72

Trim166

Add214

Sold out71

286

Net Buyers

237

Net Sellers

Smart Money Convergence

BMRN does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.

13F data as of 2026-06-30 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

Filings (14d)

Data as of 2026-07-13

2026-07-13 (/A)

BioMarin Pharmaceutical Inc. filed an 8-K with the SEC on April 27, 2026. The filing includes audited financial statements of Amicus Therapeutics for fiscal years 2023 through 2025 and unaudited pro forma condensed combined financial information giving effect to the acquisition.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

CUSIP

09061G101, 09061g101

FAQ

Who are the top institutional investors holding BIOMARIN PHARMACEUTICAL INC (BMRN)?

Major stakeholders currently include BlackRock, Inc. ($1.1B), Dodge & Cox ($822.6M), Primecap Management Co/ca/ ($801.8M). Based on the latest 13F filings, there are a total of 554 tracked investment funds and institutions maintaining positions in BMRN.

What is the overall institutional sentiment toward BMRN recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $839.9M, driven by 286 managers accumulating shares while 237 reduced their exposure.

Which institutions have been selling or reducing their BMRN positions?

In the latest period, 166 funds trimmed their holdings, and 71 managers completely exited their positions. The aggregate reported sell value was $5.7B.

Are there any notable investors adding BMRN to their portfolios?

Yes, buying activity remains notable. 72 institutions opened new positions in {ticker}, and 214 existing holders added to their shares. The total reported buy value for the quarter amounted to $5.4B.